Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psilocybin and brain training: a new frontier for aging minds?

NCT ID NCT07721467

Not yet recruiting Symptom relief Sponsor: National Institute on Aging (NIA) Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether combining psilocybin—a compound from certain mushrooms—with daily cognitive training can enhance brain plasticity in adults aged 65 and older. Participants include healthy older adults and those with mild cognitive impairment or early-stage Alzheimer's disease. One group receives cognitive training alone; the other adds two doses of psilocybin. The study aims to see if the combination leads to greater improvements in memory, attention, and thinking.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
psilocybin, a compound found in certain mushrooms, given as a 25 mg capsule twice, two weeks apart, plus daily cognitive training on a tablet for 4 weeks
What this could lead to
If it works, this could point toward a new approach to slow age-related cognitive decline and improve brain function in older adults, including those with early Alzheimer's disease.
What could go wrong
This is a Phase 2 trial, so the approach is still experimental. Psilocybin can cause temporary changes in perception and mood, and its long-term effects on cognition are not yet known. The study is also relatively small, so results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institute of Aging, Clinical Research Unit

    Baltimore, Maryland, 21224, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.